BRIEF published on 06/30/2025 at 14:05, 1 year 2 months ago Promising Phase 1b Results for invIOs's APN401 Cell Therapy in Advanced Tumors Cell Therapy Phase 1b Trial InvIOs GmbH APN401 Advanced Tumors
BRIEF published on 06/30/2025 at 14:05, 1 year 2 months ago Résultats prometteurs de phase 1b pour la thérapie cellulaire APN401 d'invIOs dans les tumeurs avancées Thérapie Cellulaire InvIOs GmbH APN401 Essai De Phase 1b Tumeurs Avancées
PRESS RELEASE published on 06/30/2025 at 14:00, 1 year 2 months ago invIOs reports promising Phase 1b results for cell therapy APN401 in advanced solid tumors invIOs reports successful Phase 1b trial results for APN401 cell therapy in advanced solid tumors, showing safety and efficacy in late-stage cancer patients Solid Tumors Cell Therapy Phase 1b Trial InvIOs APN401
BRIEF published on 12/16/2024 at 15:05, 1 year 8 months ago InvIOs to Highlight Oncology Pipeline Progress at JP Morgan Week 2025 Oncology Cancer Research Cell Therapy Glioblastoma InvIOs GmbH
BRIEF published on 12/16/2024 at 15:05, 1 year 8 months ago InvIOs mettra en avant les progrès du pipeline oncologique lors de la JP Morgan Week 2025 Thérapie Cellulaire Oncologie Glioblastome Recherche Sur Le Cancer InvIOs GmbH
PRESS RELEASE published on 12/16/2024 at 15:00, 1 year 8 months ago invIOs to present progress across oncology pipeline during JP Morgan Week 2025 invIOs GmbH to present progress in oncology pipeline at JP Morgan Week 2025, including updates on glioblastoma treatments INV501 and INV441 in collaboration with DFCI Oncology Pipeline InvIOs GmbH JP Morgan Week 2025 Glioblastoma Treatments DFCI Collaboration
BRIEF published on 10/15/2024 at 10:35, 1 year 10 months ago InvIOs Secures €8.2 Million Series A Funding for Immuno-oncology Innovations Biotechnology Fundraising Clinical Trials Immuno-oncology InvIOs GmbH
BRIEF published on 10/15/2024 at 10:35, 1 year 10 months ago InvIOS obtient un financement de série A de 8,2 millions d'euros pour des innovations en immuno-oncologie Biotechnologie Essais Cliniques Immuno-oncologie Collecte De Fonds InvIOs GmbH
PRESS RELEASE published on 10/15/2024 at 10:30, 1 year 10 months ago invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology invIOs GmbH raises €8.2 million in Series A funding to advance immuno-oncology pipeline progress through 2025, collaborating with Dana-Farber Cancer Institute Series A Funding Immuno-oncology Pipeline Progress InvIOs Dana-Farber Cancer Institute
BRIEF published on 07/17/2024 at 10:05, 2 years 1 month ago InvIOs Selects INV501 Lead Candidate for IND-Enabling Studies in Glioblastoma and Melanoma Cancer Therapy Melanoma Preclinical Studies INV501 Glioblastoma
Published on 09/01/2026 at 23:05, 2 hours 30 minutes ago Aton Announces US$30M Credit Facility with OU Moonrider
Published on 09/01/2026 at 22:30, 3 hours 5 minutes ago Algo Grande Copper Closes Oversubscribed Private Placement for $4.786 Million
Published on 09/01/2026 at 22:15, 3 hours 20 minutes ago NuRAN Wireless Announces Plans to Voluntarily Delist from the Canadian Securities Exchange
Published on 09/01/2026 at 16:10, 9 hours 25 minutes ago Sparton Signs Definitive Morrison Silver Mine Option and Joint Venture Agreement with Glen Eagle; Appoints Vice President, Corporate Development
Published on 09/02/2026 at 01:05, 30 minutes ago Clean electricity supplied 40% of new energy demand in 2025. Faster deployment and sectoral breakthroughs can cut emissions permanently, says annual Energy Transition Monitor
Published on 09/01/2026 at 22:00, 3 hours 35 minutes ago MHM CORPORATE - Publication of unaudited half-year 2026 financial information
Published on 09/01/2026 at 22:00, 3 hours 35 minutes ago MHM CORPORATE - Publication d'informations financières semestrielles 2026 non auditées
Published on 09/01/2026 at 20:07, 5 hours 28 minutes ago EQS-Adhoc: HUGO BOSS AG: HUGO BOSS TERMINATES SHARE BUYBACK PROGRAM
Published on 09/01/2026 at 20:00, 5 hours 35 minutes ago MHM Corporate: announces the launch of a capital increase with preferential subscription rights for a maximum amount of approximately €1.1 million
Published on 09/01/2026 at 19:00, 6 hours 35 minutes ago Covivio - Information on total number of voting rights and share capital
Published on 09/01/2026 at 19:00, 6 hours 35 minutes ago Covivio - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
Published on 09/01/2026 at 18:18, 7 hours 17 minutes ago TF1 - Déclaration mensuelle des actions et droits de vote - Août 2026
Published on 09/01/2026 at 18:18, 7 hours 17 minutes ago TF1 - Monthly disclosure of the total number of shares and voting rights - August 2026
Published on 09/01/2026 at 17:44, 7 hours 51 minutes ago Reporting on share buyback transactions carried out between August 18 and August 28, 2026
